세계의 림프기형 시장 : 현황 분석 및 예측(2023-2030년)

Lymphatic malformations are a form of rare disorders which are non-malignant masses consisting of fluid-filled channels due to abnormal development of lymphatic systems. These malformations are usually seen in the head and neck region of the body. Lymphatic malformations can be massive in size and even smaller malformations can potentially cause functional impairment of nearby organs and disfigurement of affected areas. Innovations in drug development and a rising number of clinical trials are leading to the growth of the market. Several other factors, such as rising research & development activities, rising healthcare expenditure, rising regulatory support, and a surge in government collaborations & partnerships are also acting as drivers of lymphatic malformation globally.

The Lymphatic Malformations Market is expected to grow at a steady rate of around 6.54% owing to the rising therapeutic developments for treating the illness. For instance, in November 2023, Palvella Therapeutics, Inc. received the U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation to QTORIN rapamycin for the treatment of microcystic lymphatic malformations. Several factors, including increasing awareness regarding lymphatic malformation, and increased investments in healthcare departments are driving the market's growth during the forecast period. Apart from this, accelerated treatment efficiency of lymphatic malformation has resulted in effective treatment procedures which are also driving this market of lymphatic malformation at a steady rate.

Based on the application, the market is bifurcated into diagnosis and treatment. The diagnosis segment held the maximum share in the global market of lymphatic malformation in 2022 owing to the rising cases of lymphatic malformation. As a result, there is a growing demand for diagnostic tools and services to screen and monitor patients for such complications. The diagnosis segment in the diabetic retinopathy market dominated as healthcare systems prioritize early detection and intervention for the welfare of patients suffering from lymphatic malformations. Technological innovations, expanding screening programs, and market expansion in emerging economies will further drive the growth of this segment in the coming years. Thus, among the applications, the diagnosis segment held a significant market share in 2022.

Based on the end user, the market is categorized into hospitals, clinics, and others. The clinic segment is expected to hold a significant share of the market in the forecast period owing to the rising awareness regarding lymphatic malformations. Clinics often serve as hubs for raising awareness about lymphatic malformations among patients and healthcare professionals. As awareness increases, more patients seek diagnosis and treatment, leading to growth in clinic visits. They are equipped with advanced diagnostic tools and techniques, such as ultrasound, MRI, and lymphoscintigraphy, which can accurately diagnose lymphatic malformations. It prioritizes patient-centered care by offering personalized treatment plans and supportive services tends to attract more patients. Thus, the clinic category will witness a higher CAGR amongst end users during the forecast period.

For a better understanding of the market adoption of lymphatic malformation, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is dominating the market in the current scenario of 2022 due to the surge in cases of lymphatic malformation, rising awareness about lymphatic malformation, and rising initiatives and investments in introducing innovative therapies. For instance, in October 2023, U.S.-based Protara Therapeutics commenced dosing in its Phase II STARBORN-1 trial investigating its cell therapy candidate for the treatment of lymphatic malformations in pediatric patients. Government organizations are initiating lymphatic malformation awareness programs for the sake of the growing cases in the region. Thus, amongst regions, North America held a significant share of the market in 2022.

Some of the major players operating in the market include Pfizer Inc.; Protara Therapeutics; Zydus Pharmaceuticals, Inc.; Palvella Therapeutics; Avalo Therapeutics, Inc.; Alkem Laboratories Ltd.; GLENMARK PHARMACEUTICALS LTD.

TABLE OF CONTENTS

1MARKET INTRODUCTION

• 1.1.Market Definitions
• 1.2.Main Objective
• 1.3.Stakeholders
• 1.4.Limitation

2RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1.Research Process of the Lymphatic Malformations Market
• 2.2.Research Methodology of the Lymphatic Malformations Market
• 2.3.Respondent Profile

3MARKET SYNOPSIS

4EXECUTIVE SUMMARY

5IMPACT OF COVID-19 ON THE LYMPHATIC MALFORMATIONS MARKET

6LYMPHATIC MALFORMATIONS MARKET REVENUE (USD BN), 2020-2030F

7MARKET INSIGHTS BY APPLICATION

• 7.1.Diagnosis
• 7.2.Treatment

8MARKET INSIGHTS BY END USER

• 8.1.Hospitals
• 8.2.Clinics
• 8.3.Others

9MARKET INSIGHTS BY REGION

• 9.1.North America
  • 9.1.1.U.S.
  • 9.1.2.Canada
  • 9.1.3.Rest of North America
• 9.2.Europe
  • 9.2.1.Germany
  • 9.2.2.U.K.
  • 9.2.3.France
  • 9.2.4.Italy
  • 9.2.5.Spain
  • 9.2.6.Rest of Europe
• 9.3.Asia-Pacific
  • 9.3.1.China
  • 9.3.2.Japan
  • 9.3.3.India
  • 9.3.4.Rest of Asia-Pacific
• 9.4.Rest of World

10LYMPHATIC MALFORMATIONS MARKET DYNAMICS

• 10.1.Market Drivers
• 10.2.Market Challenges
• 10.3.Impact Analysis

11LYMPHATIC MALFORMATIONS MARKET OPPORTUNITIES

12LYMPHATIC MALFORMATIONS MARKET TRENDS

13DEMAND AND SUPPLY-SIDE ANALYSIS

• 13.1.Demand Side Analysis
• 13.2.Supply Side Analysis

14VALUE CHAIN ANALYSIS

15COMPETITIVE SCENARIO

• 15.1.Competitive Landscape
  • 15.1.1.Porters Fiver Forces Analysis

16COMPANY PROFILED

• 16.1.Pfizer Inc.
• 16.2.Protara Therapeutics
• 16.3.Zydus Pharmaceuticals, Inc.
• 16.4.Palvella Therapeutics
• 16.5.Avalo Therapeutics, Inc.
• 16.6.Alkem Laboratories Ltd.
• 16.7.GLENMARK PHARMACEUTICALS LTD.

17DISCLAIMER